Skip to main content
. 2003 Oct 1;5(6):R347–R351. doi: 10.1186/ar1005

Table 3.

American College of Rheumatology core outcomes at 3 months

Etanercept plus methotrexate Etanercept only P value
SJC 4.40 ± 0.57 5.56 ± 0.84 Not significant
TJC 4.78 ± 0.73 5.25 ± 0.90 Not significant
HAQ 1.20 ± 0.10 1.50 ± 0.12 Not significant
Patient global 28.0 ± 3.0 45.0 ± 4.0 < 0.001
Patient pain 27.6 ± 3.4 44.2 ± 4.7 < 0.005
Physician global 1.17 ± 0.09 1.55 ± 0.12 < 0.02
ESR 18.6 ± 1.8 22.6 ± 3.0 Not significant

Values presented as mean ± standard error of the mean. Comparisons are by unpaired Student t test. ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire disability index; patient global, patient assessment of global health by 100 mm visual analogue scale; patient pain, patient assessment of pain by 100 mm visual analogue scale; physician global, physician's assessment of global disease activity by five-point scale (0–4); SJC, swollen joint count (based on 28 joints); TJC, tender joint count (based on 28 joints).